tiprankstipranks
Trending News
More News >
Matinas BioPharma (MTNB)
:MTNB
US Market

Matinas BioPharma (MTNB) Income Statement

Compare
1,538 Followers

Matinas BioPharma Income Statement

Last quarter (Q3 2025), Matinas BioPharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Matinas BioPharma's net income was $-2.15M. See Matinas BioPharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 1.10M$ 3.19M$ 33.00K$ 158.33K
Gross Profit
$ 0.00$ 1.10M$ -13.49M$ -14.55M$ -14.20M
Operating Expenses
$ 24.59M$ 24.86M$ 11.10M$ 10.19M$ 10.01M
Depreciation and Amortization
$ 972.00K$ 941.00K$ 356.00K$ 280.00K$ 290.02K
EBITDA
$ -19.19M$ -22.82M$ -24.23M$ -24.45M$ -23.92M
Operating Income
$ -24.59M$ -23.77M$ -24.59M$ -24.73M$ -24.21M
Other Income/Expenses
$ 262.00K$ 824.00K$ 3.59M$ 1.45M$ 1.76M
Pretax Income
$ -24.33M$ -22.94M$ -21.00M$ -23.28M$ -22.45M
Net Income
$ -24.25M$ -22.94M$ -21.00M$ -23.28M$ -22.45M
Per Share Metrics
Basic EPS
$ -4.98$ -5.28$ -3.00$ -5.04$ -5.23
Diluted EPS
$ -4.98$ -5.28$ -3.00$ -5.04$ -5.23
Weighted Average Shares Outstanding
4.87M 4.35M 4.34M 4.20M 3.94M
Weighted Average Shares Outstanding (Diluted)
4.87M 4.35M 4.34M 4.20M 3.94M
Currency in USD

Matinas BioPharma Earnings and Revenue History